In The News

Press

Study of Comprehensive Medication Measurement Offers Promise to Improve Adherence, Accuracy of Medical Record, and Safety of Patients on Multiple Medications

Franklin, TN, November 6, 2018 – Precera Bioscience, Inc. (“Precera”) announces the publication of Assessment of Patient Medication Adherence, Medical Record Accuracy, and Medication Blood Concentrations for Prescription and Over-the-Counter Medications in JAMA Network Open.

Precera Bioscience Appoints New CEO and Leadership Team

Franklin, TN, May 17, 2018 – Precera Bioscience, Inc. (“Precera”), formerly Sano, appointed Pamela Weir as President and Chief Executive Officer effective January 1, 2018.  Ms. Weir brings 30 years of pharmaceutical experience across diverse functions of Commercial, R&D, Operations, Business Development and General Management.

Media Inquiries

Ginny Pennekamp
gpennekamp@precera.com
(615) 933-0900

About Precera

Precera is a biosciences company dedicated to individualizing prescribing through cutting-edge science. Precera offers the only clinical tools that address all aspects of medication therapy management: adherence, drug-drug interactions, medical reconciliation and dose tailoring. In addition to products available to hospitals and clinics, Precera’s platform can also optimize clinical drug development. The company has a history of partnering with healthcare companies and academic institutions, that share its mission to optimize patient medication therapy.